Ben joined Pivotal Bioventure Partners as an Operating Partner from April, 2017. Ben has overall 24+ years’ extensive experience of global pharmaceutical R&D and business development in addition to building small biotech and CRO.  Before joining us, Dr. Ben Ni was CEO of iPharma (H.K) Ltd  (and i-Bridge operating partner) and from 2010-2017, Ben was the Head of External Innovation & Partnering, Strategy and Business Development, responsible for Sanofi licensing, transaction & partnering, from Asia pacific region. Since 1994, Ben worked as member of senior management team  in several global healthcare/pharmaceutical companies such as Eli Lilly/US (Action Group Chair), Covance (General Manager, Greater China), GSK (Neurodegenerative Disease Center, Global head ) where Ben has the proven track record of transitioning compounds from drug discovery/research phase into clinical development in several therapeutic areas and  plays pivotal roles in global R&D, Clinical service management in China. His value-add lies in broad and diverse scientific and business management expertise/knowledge in multi sectors of global healthcare industry under multi-culture environment in US and Asia.

Ben has >40 publications in top international journals including Science, PNAS, five book chapters and four granted US patents. Ben is also adjunct professor in several universities in US and Singapore. Ben has been invited speaker in > 60 international conferences and professional seminars.

Ben holds a Ph. D in molecular pharmacology from University of Toronto under fellowship and post-doctoral fellowship in Clinical Pharmacology from National Institute of Health.